Canaccord Genuity Group Lowers Pulmonx (NASDAQ:LUNG) Price Target to $5.00

Pulmonx (NASDAQ:LUNG) had its target price cut by equities researchers at Canaccord Genuity Group from $6.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 210.56% from the company’s current price.

A number of other research analysts have also recently issued reports on the company. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of Pulmonx in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.38.

Pulmonx Price Performance

Shares of Pulmonx stock traded up $0.17 during trading on Thursday, hitting $1.61. 1,749,305 shares of the stock traded hands, compared to its average volume of 395,841. Pulmonx has a 52 week low of $1.31 and a 52 week high of $8.12. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62. The firm’s fifty day moving average is $1.77 and its 200-day moving average is $1.79. The stock has a market cap of $66.41 million, a price-to-earnings ratio of -1.14 and a beta of 0.07.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.14. The firm had revenue of $22.60 million during the quarter, compared to analyst estimates of $21.73 million. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. Research analysts expect that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Buying and Selling

In other Pulmonx news, CEO Glendon E. French III sold 67,813 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $96,972.59. Following the completion of the transaction, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. This represents a 4.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders sold 98,265 shares of company stock worth $140,519. Corporate insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LUNG. Corton Capital Inc. bought a new position in Pulmonx in the second quarter worth about $32,000. Cerity Partners LLC bought a new position in shares of Pulmonx in the 4th quarter worth about $27,000. Opal Capital LLC purchased a new position in Pulmonx during the 4th quarter valued at about $29,000. Regatta Capital Group LLC bought a new stake in Pulmonx during the fourth quarter worth about $30,000. Finally, Lazard Asset Management LLC bought a new stake in Pulmonx during the fourth quarter worth about $31,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx News Summary

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year senior secured credit facility for up to $60M (initial $40M drawn to refinance existing debt, $20M available subject to revenue milestones), extending debt maturities to 2031 and improving near‑term liquidity. Credit Facility Release
• Positive Sentiment: Q4 2025 results beat expectations: EPS loss of $0.25 vs. consensus -$0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year — evidence management is stabilizing operations. Earnings Release
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating and kept a $14 price target, which can attract momentum buyers given the large upside versus current levels. Analyst Note
• Neutral Sentiment: Profitability levers look better: Q4 gross margin improved to ~78% and operating expenses declined ~11%, but sustained recovery depends on revenue re‑acceleration. Financial Results
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), which caps near‑term upside and signals slower top‑line momentum. Guidance
• Negative Sentiment: Multiple insiders (including the CEO and general counsel) sold shares on March 2 — several Form 4 filings increase perceived selling pressure and may weigh on sentiment. SEC Filing
• Negative Sentiment: The new facility is relatively expensive (SOFR + 7.0% with a 3.75% floor and 2% PIK option) and includes warrants — it improves runway but raises interest costs and potential dilution. Financing Details

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.